Page 84 - Read Online

Pandey et al. J Transl Genet Genom 2021;5:22-36 I http://dx.doi.org/10.20517/jtgg.2020.45 Page 35

hydroxyurea. Multicenter Study of Hydroxyurea. Blood 1997;89:1078-88.
22. Davies SC, Gilmore A. The role of hydroxyurea in the management of sickle cell disease. Blood Reviews 2003;17:99-109.
23. Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease
pathophysiology. Blood 2016;127:801-9.
24. Ansari J, Gavins FNE. Ischemia-Reperfusion Injury in Sickle Cell Disease: From Basics to Therapeutics. Am J Pathol 2019;189:706-18.
25. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year
follow-up. Am J Hematol 2010;85:403-8.
26. Hankins JS, Aygun B, Nottage K, et al. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell
anemia. Medicine (Baltimore) 2014;93:e215.
27. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood
1992;79:2555-65.
28. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in
children with sickle cell disease. Blood 2004;103:2039-45.
29. Estepp JH, Smeltzer MP, Kang G, et al. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during
hydroxyurea therapy. Am J Hematol 2017;92:1333-9.
30. Estepp JH, Winter B, Johnson M, Smeltzer MP, Howard SC, Hankins JS. Improved hydroxyurea effect with the use of text messaging in
children with sickle cell anemia. Pediatr Blood Cancer 2014;61:2031-6.
31. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of
the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-22.
32. Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for
children with sickle cell anemia. Blood 2011;118:4985-91.
33. Paule I, Sassi H, Habibi A, et al. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a
basis for optimizing the dosing regimen. Orphanet J Rare Dis 2011;6:30.
34. Wiczling P, Liem RI, Panepinto JA, et al. Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell
disease. J Clin Pharmacol 2014;54:1016-22.
35. Estepp JH, Melloni C, Thornburg CD, et al. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with
sickle cell anemia. J Clin Pharmacol 2016;56:298-306.
36. Thornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr
2010;156:415-9.
37. Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and
fears of toxicities. Expert Rev Hematol 2010;3:255-60.
38. Walker AL, Franke RM, Sparreboom A, Ware RE. Transcellular movement of hydroxyurea is mediated by specific solute carrier
transporters. Exp Hematol 2011;39:446-56.
39. Walker AL, Lancaster CS, Finkelstein D, Ware RE, Sparreboom A. Organic anion transporting polypeptide 1B transporters modulate
hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol 2013;305:C1223-9.
40. Colvin M, Bono VH. The Enzymatic Reduction of Hydroxyurea to Urea by Mouse Liver. Cancer Res 1970;30:1516-9.
41. Andrae U. Evidence for the involvement of cytochrome P-450-dependent monooxygenase(s) in the formation of genotoxic metabolites
from N-hydroxyurea. Biochem Biophys Res Commun 1984;118:409-15.
42. Huang J, Kim-Shapiro DB, King SB. Catalase-mediated nitric oxide formation from hydroxyurea. J Med Chem 2004;47:3495-501.
43. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble
guanylyl cyclase. J Clin Invest 2003;111:231-9.
44. Ikuta T, Ausenda S, Cappellini MD. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent
protein kinase pathway. Proc Natl Acad Sci U S A 2001;98:1847-52.
45. Pace BS, Qian XH, Sangerman J, et al. p38 MAP kinase activation mediates γ-globin gene induction in erythroid progenitors. Exp
Hematol 2003;31:1089-96.
46. Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.
Pediatr Blood Cancer 2012;59:365-71.
47. Rodriguez GI, Kuhn JG, Weiss GR, et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood
1998;91:1533-41.
48. Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet 1998;34:347-58.
49. Fabricius E, Rajewsky F. Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Etud Clin Biol 1971;16:679-83.
50. Adamson RH, Ague SL, Hess SM, Davidson JD. The distribution, excretion and metabolism of hydroxyurea-C14. J Pharmacol Exp Ther
1965;150:322-34.
51. Kovacic P. Hydroxyurea (therapeutics and mechanism): Metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical
applications. Med Hypotheses 2011;76:24-31.
52. DiPiro JT. Concepts in clinical pharmacokinetics. ASHP 2010.
53. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to
pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2013;2:e38.
54. Dong M, McGann PT, Mizuno T, Ware RE, Vinks AA. Development of a pharmacokinetic-guided dose individualization strategy for
hydroxyurea treatment in children with sickle cell anaemia. Br J Clin Pharmacol 2016;81:742-52.